Jazz Pharmaceuticals plc (the "Company") is filing this Current Report on Form 8-K to present the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012 that give effect to the two transactions consummated during the year ended December 31, 2012 described below in Item 9.01(b).

(b) Pro Forma Financial Information

The Company completed two transactions during the year ended December 31, 2012 for which pro forma financial information has previously been included in its filings with the Securities and Exchange Commission. On January 18, 2012, Azur Pharma Public Company Limited ("Azur") and Jazz Pharmaceuticals, Inc. ("JPI") completed a merger transaction (the "Azur Merger"). For accounting purposes, the Azur Merger was treated as a "reverse acquisition" of Azur by JPI, which was considered the accounting acquirer, and the financial statements of JPI became the historical financial statements of the Company. On June 12, 2012, the Company completed the acquisition of EUSA Pharma, Inc. (the "EUSA Acquisition").

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012, giving effect to the Azur Merger and the EUSA Acquisition, and the notes related thereto, are included as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.

(d) Exhibits

Exhibit
Number       Description

99.1         Unaudited pro forma condensed combined statement of operations for the
             year ended December 31, 2012.